» Articles » PMID: 11517174

S179D-human PRL, a Pseudophosphorylated Human PRL Analog, is an Agonist and Not an Antagonist

Overview
Journal Endocrinology
Specialty Endocrinology
Date 2001 Aug 23
PMID 11517174
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

For many years, our group has been involved in the development of human PRL antagonists. In two recent publications, S179D-human PRL, a human PRL analog designed to mimic a putative S179-phosphorylated human PRL, was reported to be a highly potent antagonist of human PRL-induced proliferation and signaling in rat Nb2 cells. We prepared this analog with the aim of testing it in various bioassays involving the homologous, human PRL receptor. In our hands, S179D- human PRL was able to stimulate 1) the proliferation of rat Nb2 cells and of human mammary tumor epithelial cells (T-47D), 2) transcriptional activation of the lactogenic hormone response element-luciferase reporter gene, and 3) activation of the Janus kinase/signal transducer and activator of transcription and MAPK pathways. Using the previously characterized antagonist G129R-human PRL as a control, we failed to observe any evidence for antagonism of S179D-human PRL toward any of the human PRL-induced effects analyzed, including cell proliferation, transcriptional activation, and signaling. In conclusion, our data argue that S179D-human PRL is an agonist displaying slightly reduced affinity and activity due to local alteration of receptor binding site 1, and that the antagonistic properties previously attributed to S179D-human PRL cannot be confirmed in any of the assays analyzed in this study.

Citing Articles

Prolactin-mediated regulation of lipid biosynthesis genes in vivo in the lactating mammary epithelial cell.

Rudolph M, Russell T, Webb P, Neville M, Anderson S Am J Physiol Endocrinol Metab. 2011; 300(6):E1059-68.

PMID: 21467304 PMC: 3118595. DOI: 10.1152/ajpendo.00083.2011.


The rhythmic secretion of mating-induced prolactin secretion is controlled by prolactin acting centrally.

Helena C, McKee D, Bertram R, Walker A, Freeman M Endocrinology. 2009; 150(7):3245-51.

PMID: 19282380 PMC: 2703506. DOI: 10.1210/en.2009-0095.


Analysis of site-specific histidine protonation in human prolactin.

Tettamanzi M, Keeler C, Meshack S, Hodsdon M Biochemistry. 2008; 47(33):8638-47.

PMID: 18652486 PMC: 2766358. DOI: 10.1021/bi800444t.


From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics.

Clevenger C, Zheng J, Jablonski E, Galbaugh T, Fang F J Mammary Gland Biol Neoplasia. 2008; 13(1):147-56.

PMID: 18246318 DOI: 10.1007/s10911-008-9074-8.


Rational design of competitive prolactin/growth hormone receptor antagonists.

Tallet E, Rouet V, Jomain J, Kelly P, Bernichtein S, Goffin V J Mammary Gland Biol Neoplasia. 2008; 13(1):105-17.

PMID: 18219565 DOI: 10.1007/s10911-008-9066-8.